Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label randomized neoadjuvant study of ARV-471 vs anastrozole in ER+/HER2- breast cancer
2021-005081-17Phase 2Completed
- Sponsor
- Arvinas
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing ARV-471 arm with Anastrozole arm (2 arms). Primary endpoint: Percent change in Ki-67 expression between baseline and Cycle 1 Day 15 tumor biopsies. Started Aug 2022; status: completed.
02
Drugs
vepdegestrantanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-005081-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005081-17.